Earnings Call Summary | Akoya Biosciences(AKYA.US) Q1 2024 Earnings Conference
Earnings Call Summary | Akoya Biosciences(AKYA.US) Q1 2024 Earnings Conference
The following is a summary of the Akoya Biosciences, Inc. (AKYA) Q1 2024 Earnings Call Transcript:
以下是Akoya Biosciences, Inc.（AKYA）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Akoya Biosciences reports Q1 2024 total revenue of $18.4 million, highlighting a shortfall due to various challenges including capital expenditure pressures and transitions from third-party to internal manufacturing.
Reagent revenue constituted $7 million, marking a 23% increase from the previous year.
Operating expenses reached $30 million, while maintaining cash and marketable securities at approximately $61.6 million.
Despite revenue shortfall, Akoya expects a recovery throughout 2024 and plans to achieve operating cash flow breakeven by the end of the year.
Akoya Biosciences報告稱，2024年第一季度總收入爲1,840萬美元，這突顯了包括資本支出壓力和從第三方向內部製造的過渡在內的各種挑戰造成的短缺。
試劑收入爲700萬美元，比上年增長23％。
運營支出達到3000萬美元，同時將現金和有價證券維持在約6,160萬美元。
儘管收入不足，但Akoya預計整個2024年將出現復甦，並計劃在年底之前實現運營現金流盈虧平衡。
Business Progress:
業務進展：
Akoya advances its business progress by launching a new manufacturing center that aims to improve operational efficiency and increase gross margins.
Their strategic partnerships with Acrivon Therapeutics, Shanghai KR Pharmtech, and NeraCare aim to innovate in companion diagnostics, expand into the Chinese market and personalize therapy selection for early-stage melanoma patients.
Akoya has seen an increase in demand for grant application support in the Chinese market, reflecting potential future growth.
Despite manufacturing transition issues that affected the financial performance, Akoya is focusing on improving top-line performance and margin performance for the rest of the year.
Akoya通過啓動新的製造中心來推進其業務進展，該中心旨在提高運營效率和增加毛利率。
他們與Acrivon Therapeutics、上海KR Pharmtech和NeraCare的戰略合作伙伴關係旨在創新伴隨診斷，擴展到中國市場，併爲早期黑色素瘤患者提供個性化治療選擇。
Akoya看到中國市場對補助金申請支持的需求增加，這反映了未來的潛在增長。
儘管製造業轉型問題影響了財務業績，但Akoya仍專注於改善今年剩餘時間的營收表現和利潤表現。
More details: Akoya Biosciences IR
更多詳情： Akoya 生物科學紅外線
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。